# NCT04576156 (NCT04576156)

> A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04576156
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Geron Corporation
- Conditions: Myelofibrosis
- Interventions: Imetelstat; Best Available Therapy (BAT)
- Enrollment: 327
- Primary outcome: Overall survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 18
- Podcasts: 11
- X threads: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04576156

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04576156", "email": "<work email>"}; the inbox owner confirms by the emailed link.